Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …

Background Immunotherapy has recently emerged as a treatment strategy which stimulates
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …

Immune checkpoint blockade (ICB) benefits some patients with triple-negative breast
cancer, but what distinguishes responders from non-responders is unclear. Because ICB …

Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive
intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor …

Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

Antibody-drug conjugates (ADCs) and immunotherapy have prompted a revolution in the
treatment of cancer. However, only a limited fraction of patients obtained a long-term benefit; …

Background Cuproptosis is a copper-dependent cell death mechanism that is associated
with tumor progression, prognosis, and immune response. However, the potential role of …

Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …

Talimogene laherparepvec (T-VEC) is an oncolytic virus hypothesized to enhance triple-
negative breast cancer (TNBC) responses to neoadjuvant chemotherapy (NAC). This article …

Simple Summary The genomics-based concept of precision medicine began to emerge
following the completion of the Human Genome Project. In contrast to evidence-based …